Miromatrix Medical Inc. (MIRO)

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“Merger Sub”), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“Merger Sub”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon th.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Miromatrix Medical Inc. (NasdaqCM: MIRO) to United Therapeutics Corporation (NasdaqGS: UTHR). Under the terms of the proposed transaction, shareholders of Miromatrix will receive $3.25 in cash for each share of Miromatrix that they own, as well as an additional $1.75 per share in cash upon the achievement of a.

MILWAUKEE , Oct. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Miromatrix (Nasdaq: MIRO) for possible breaches of fiduciary duty and other violations of law in its transaction with United Therapeutics. Click here to learn how to join the action https://www.ademilaw.com/case/Miromatrix-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shares in the artificial human organs specialist Miromatrix Medical Inc. jumped 25% in premarket trading following the announcement of its acquisition by United Therapeutics Corporation (NASDAQ:UTHR) for up to $140 million.

Miromatrix Medical (NASDAQ: MIRO ) stock is rocketing higher on Monday after announcing an acquisition deal with United Therapeutics (NASDAQ: UTHR ). That deal has United Therapeutics agreeing to acquire Miromatrix Medical for $91 million in cash, which comes to $3.25 per share.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Miromatrix Medical Inc. (NASDAQ: MIRO) to United Therapeutics Corporation is fair to Miromatrix shareholders. Under the terms of the proposed transaction, United Therapeutics would acquire all outstanding shares of Miromatrix for $3.25 per share in cash and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's kidney prod.

Miromatrix Medical Inc.'s stock MIRO, -2.80% jumped 230% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. UTHR, -2.30% for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix's development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. and EDEN PRAIRIE, Minn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology company with six FDA-approved therapies to address rare, life-threatening condit.

EDEN PRAIRIE, Minn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it will be presenting at the 2023 International Society for Organ Donation and Procurement ("ISODP") Organ Donation Congress in Las Vegas, NV on October 18-21 at Mandalay Bay Resort.

EDEN PRAIRIE, Minn., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that CEO Jeff Ross will present at the 2023 Cell & Gene Meeting on the Mesa in Carlsbad, CA. The three-day event, held this year on October 10-12, will feature presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies.

EDEN PRAIRIE, Minn., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on September 11th, 2023.

EDEN PRAIRIE, Minn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced its participation in the upcoming Alliance for Regenerative Medicine (ARM) Tissue Engineering and Therapeutics Workshop held on September 6, 2023.

Miromatrix Medical Inc. (NASDAQ:MIRO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Max Forgan - Gilmartin Investor Relations Jeff Ross - Chief Executive Officer Jim Douglas - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Phillip Dantoin - Piper Sandler Operator Good day, and welcome to the Miromatrix Medical, Inc. Second Quarter 2023 Earnings Conference Call. All participants' will be in listen-only mode.